Who are brivaracetam (BRV) tablet's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Keppra, All registered antiepileptic drugs, intravenous levetireacetam, Levetiracetam (LEV), LEV, Standard dose levetiracetam.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/brivaracetam-brv-tablet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

brivaracetam (BRV) tablet — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

brivaracetam (BRV) tablet (brivaracetam (BRV) tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SV2A receptor agonist. Area: Neurology.

phase 3 SV2A receptor agonist SV2A Neurology Small molecule Live · refreshed every 30 min

Target snapshot

brivaracetam (BRV) tablet (brivaracetam (BRV) tablet) — UCB Biopharma SRL. Brivaracetam is a selective, high-affinity SV2A receptor agonist.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
brivaracetam (BRV) tablet TARGET	brivaracetam (BRV) tablet	UCB Biopharma SRL	phase 3	SV2A receptor agonist	SV2A
Keppra	levetiracetam	Generic (originally UCB Pharma)	marketed	Antiepileptic agent	Synaptic vesicle protein SV2A	1999-11-30
All registered antiepileptic drugs	All registered antiepileptic drugs	UMC Utrecht	marketed	Antiepileptic drugs (heterogeneous class)	Multiple targets including voltage-gated sodium channels, GABA receptors, calcium channels, SV2A, and others depending on specific agent
intravenous levetireacetam	intravenous levetireacetam	ayesha tariq	marketed	Antiepileptic agent	SV2A (synaptic vesicle protein 2A)
Levetiracetam (LEV)	Levetiracetam (LEV)	UCB Japan Co. Ltd.	marketed	Antiepileptic drug (AED)	SV2A (synaptic vesicle protein 2A)
LEV	LEV	GlaxoSmithKline	marketed	Antiepileptic agent	SV2A (synaptic vesicle glycoprotein 2A)
Standard dose levetiracetam	Standard dose levetiracetam	Mario Negri Institute for Pharmacological Research	marketed	Antiepileptic agent	SV2A (synaptic vesicle protein 2A)

Recent regulatory actions (last 90 days)

2026-05-08 — Keppra · FDA · approved · US · Generic (originally UCB Pharma)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-09-03 — Keppra · 8163306 · Formulation · US
2027-10-31 — Keppra · 8431156 · Formulation · US
2027-10-31 — Keppra · 8470367 · Formulation · US
2028-09-17 — Keppra · 7858122 · Formulation · US
2031-06-07 — Keppra · 8802142 · Formulation · US
2031-12-07 — Keppra · 8802142*PED · Compound · US
2034-03-14 — Keppra · 11160786 · Formulation · US
2034-03-14 — Keppra · 9669009 · Method of Use · US
2034-03-14 — Keppra · 9339489 · Formulation · US

Sponsor landscape (SV2A receptor agonist class)

UCB Biopharma SRL · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). brivaracetam (BRV) tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/brivaracetam-brv-tablet. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing